{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:26:05Z","timestamp":1790691965792,"version":"4.1.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Nuovo Soldati Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jare.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:32:50Z","timestamp":1553862770000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["A review on hepatitis D: From virology to new therapies"],"prefix":"10.1016","volume":"17","author":[{"given":"Nathalie","family":"Mentha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Alfaiate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2019.03.009_b0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0010","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0015","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jare.2019.03.009_b0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0025","article-title":"Devil hepatitis D: an orphan disease or largely underdiagnosed?","author":"Wedemeyer","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0030","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","author":"Chen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0035","article-title":"Hepatitis D prevalence: problems with extrapolation to global population estimates","author":"Stockdale","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0040","article-title":"A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians","author":"Chen","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0045","doi-asserted-by":"crossref","first-page":"e20180289","DOI":"10.1590\/0037-8682-0289-2018","article-title":"Hepatitis delta prevalence in South America: a systematic review and meta-analysis","volume":"52","author":"Scarponi","year":"2019","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.jare.2019.03.009_b0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jvh.12991","article-title":"High prevalence and diversity of hepatitis B and hepatitis delta virus in Gabon","volume":"26","author":"Groc","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0055","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1038\/s41598-018-30078-5","article-title":"High prevalence of hepatitis delta virus in Cameroon","volume":"8","author":"Butler","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2019.03.009_b0060","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.8210","article-title":"Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis","volume":"13","author":"Amini","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jare.2019.03.009_b0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.15403\/jgld.2014.1121.244.dtv","article-title":"Hepatitis delta virus infection in Romania: prevalence and risk factors","volume":"24","author":"Gheorghe","year":"2015","journal-title":"J Gastrointest Liver Dis JGLD"},{"key":"10.1016\/j.jare.2019.03.009_b0070","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.3748\/wjg.v20.i24.7635","article-title":"Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy","volume":"20","author":"Sagnelli","year":"2014","journal-title":"World J Gastroenterol WJG"},{"key":"10.1016\/j.jare.2019.03.009_b0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s15010-016-0956-1","article-title":"Hepatitis delta infection in Italian patients: towards the end of the story?","volume":"45","author":"Stroffolini","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jare.2019.03.009_b0080","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/MEG.0000000000001163","article-title":"Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain","volume":"30","author":"Aguilera","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcv.2013.11.016","article-title":"Increasing prevalence of HDV\/HBV infection over 15 years in France","volume":"59","author":"Servant-Delmas","year":"2014","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0090","article-title":"Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: the Hepatitis Delta International Network (HDIN)","author":"Wranke","year":"2017","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jare.2019.03.009_b0095","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0100","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz001","article-title":"Prevalence of Hepatitis B and Hepatitis D virus infections in the United States, 2011\u20132016","author":"Patel","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jare.2019.03.009_b0110","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/S0016-5085(17)33657-0","article-title":"Prevalence of hepatitis delta virus (HDV) infection in the United States: results from an ICD-10 review","volume":"152","author":"Martins","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0168-8278(99)80185-8","article-title":"Intrafamilial transmission of hepatitis delta virus: molecular evidence","volume":"30","author":"Niro","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11894-013-0365-x","article-title":"Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery","volume":"16","author":"Noureddin","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jare.2019.03.009_b0125","first-page":"7","article-title":"Hepatitis D virus: an update","volume":"31","author":"Pascarella","year":"2011","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jare.2019.03.009_b0130","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/infdis\/162.5.1170","article-title":"Heterosexual transmission of hepatitis delta virus in the general population of an area endemic for hepatitis B virus infection: a prospective study","volume":"162","author":"Liaw","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0135","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.3748\/wjg.v20.i24.7665","article-title":"Hepatitis B virus lineages in mammalian hosts: potential for bidirectional cross-species transmission","volume":"20","author":"Bonvicino","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jare.2019.03.009_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/v10120720","article-title":"A Divergent hepatitis D-Like agent in birds","volume":"10","author":"Wille","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jare.2019.03.009_b0145","article-title":"Identification of a novel deltavirus in boa constrictor","author":"Hetzel","year":"2018","journal-title":"BioRxiv"},{"key":"10.1016\/j.jare.2019.03.009_b0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coviro.2016.01.022","article-title":"Pathogenesis by subviral agents: viroids and hepatitis delta virus","volume":"17","author":"Flores","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0155","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3748\/wjg.v20.i11.2971","article-title":"Host RNA circles and the origin of hepatitis delta virus","volume":"20","author":"Taylor","year":"2014","journal-title":"World J Gastroenterol WJG"},{"key":"10.1016\/j.jare.2019.03.009_b0160","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1099\/jgv.0.001150","article-title":"ICTV virus taxonomy profile: deltavirus","volume":"99","author":"Magnius","year":"2018","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0165","first-page":"151","article-title":"Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades?","volume":"307","author":"D\u00e9ny","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jare.2019.03.009_b0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2015.08.009","article-title":"Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options","volume":"122","author":"Alfaiate","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jare.2019.03.009_b0175","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0180","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1099\/vir.0.013615-0","article-title":"Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region","volume":"90","author":"Gomes-Gouv\u00eaa","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/174.5.920","article-title":"Hepatitis B virus (HBV)\/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F","volume":"174","author":"Casey","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0190","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1128\/JVI.00346-14","article-title":"Support of the infectivity of hepatitis delta virus particles by the envelope proteins of different genotypes of hepatitis B virus","volume":"88","author":"Freitas","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0195","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1073\/pnas.77.10.6124","article-title":"delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees","volume":"77","author":"Rizzetto","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0205","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1017\/S1355838202026432","article-title":"Hepatitis delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm","volume":"8","author":"Tavanez","year":"2002","journal-title":"RNA N Y N"},{"key":"10.1016\/j.jare.2019.03.009_b0210","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1128\/JVI.77.19.10314-10326.2003","article-title":"Determination of the multimerization state of the hepatitis delta virus antigens in vivo","volume":"77","author":"Cornillez-Ty","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0215","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1128\/JVI.00443-14","article-title":"Hepatitis delta antigen requires a flexible quasi-double-stranded RNA structure to bind and condense hepatitis delta virus RNA in a ribonucleoprotein complex","volume":"88","author":"Griffin","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0220","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1128\/JVI.76.8.3709-3719.2002","article-title":"Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA","volume":"76","author":"Gudima","year":"2002","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.jare.2019.03.009_b0225","first-page":"821","article-title":"Structural basis of the oligomerization of hepatitis delta antigen","volume":"1998","author":"Zuccola","year":"1993","journal-title":"Struct Lond Engl"},{"key":"10.1016\/j.jare.2019.03.009_b0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jare.2019.03.009_b0235","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.1073\/pnas.83.22.8774","article-title":"Structure and replication of the genome of the hepatitis delta virus","volume":"83","author":"Chen","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0240","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1128\/JVI.76.8.3928-3935.2002","article-title":"Genomic but not antigenomic hepatitis delta virus RNA is preferentially exported from the nucleus immediately after synthesis and processing","volume":"76","author":"Macnaughton","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0245","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1128\/JVI.74.16.7204-7210.2000","article-title":"Origin of hepatitis delta virus mRNA","volume":"74","author":"Gudima","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0250","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/jvi.62.12.4439-4444.1988","article-title":"Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus","volume":"62","author":"Kuo","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2893.2010.01321.x","article-title":"Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy","volume":"18","author":"Coffin","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0260","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/02648725.2018.1474324","article-title":"Hepatitis B virus lymphotropism: emerging details and challenges","volume":"34","author":"Joshi","year":"2018","journal-title":"Biotechnol Genet Eng Rev"},{"key":"10.1016\/j.jare.2019.03.009_b0265","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/jvi.63.4.1612-1618.1989","article-title":"Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks","volume":"63","author":"Negro","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-3527(09)74003-5","article-title":"Replication of the hepatitis delta virus RNA genome","volume":"74","author":"Taylor","year":"2009","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.jare.2019.03.009_b0275","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/jvi.68.6.4063-4066.1994","article-title":"The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus","volume":"68","author":"Sureau","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0280","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1128\/JVI.01495-07","article-title":"Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange","volume":"81","author":"Abou-Jaoud\u00e9","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058340","article-title":"Proteoglycans act as cellular hepatitis delta virus attachment receptors","volume":"8","author":"Lamas Longarela","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jare.2019.03.009_b0290","first-page":"122","article-title":"Role of glycosaminoglycans for binding and infection of hepatitis B virus","volume":"10","author":"Leistner","year":"2008","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jare.2019.03.009_b0295","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0305","first-page":"00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2012","journal-title":"ELife"},{"key":"10.1016\/j.jare.2019.03.009_b0310","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0315","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1128\/MCB.20.16.6030-6039.2000","article-title":"RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases","volume":"20","author":"Modahl","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jare.2019.03.009_b0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2009.02.007","article-title":"The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III","volume":"386","author":"Greco-Stewart","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.jare.2019.03.009_b0325","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/291297a0","article-title":"DNA-dependent RNA polymerase II of plant origin transcribes viroid RNA into full-length copies","volume":"291","author":"Rackwitz","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.jare.2019.03.009_b0330","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.virol.2006.08.010","article-title":"The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome","volume":"357","author":"Greco-Stewart","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.jare.2019.03.009_b0335","first-page":"833","article-title":"[Hepatitis delta virus replication and the role of the small hepatitis delta protein S-HDAg]","volume":"34","author":"Abeywickrama-Samarakoon","year":"2018","journal-title":"Med Sci MS"},{"key":"10.1016\/j.jare.2019.03.009_b0340","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1073\/pnas.88.19.8490","article-title":"The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus","volume":"88","author":"Chang","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0345","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/JVI.74.16.7375-7380.2000","article-title":"The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication","volume":"74","author":"Modahl","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0350","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/jvi.63.5.1945-1950.1989","article-title":"Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen","volume":"63","author":"Kuo","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0355","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1057925","article-title":"Stimulation of RNA polymerase II elongation by hepatitis delta antigen","volume":"293","author":"Yamaguchi","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jare.2019.03.009_b0360","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1261\/rna.1782209","article-title":"Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication","volume":"15","author":"Cao","year":"2009","journal-title":"RNA N Y N"},{"key":"10.1016\/j.jare.2019.03.009_b0365","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1073\/pnas.97.1.424","article-title":"A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs","volume":"97","author":"Reid","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0370","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jare.2019.03.009_b0375","first-page":"123","article-title":"Control of ADAR1 editing of hepatitis delta virus RNAs","volume":"353","author":"Casey","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jare.2019.03.009_b0380","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1073\/pnas.232416799","article-title":"Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1","volume":"99","author":"Wong","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0385","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2893.2005.00663.x","article-title":"The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells","volume":"13","author":"Hartwig","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0390","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4254\/wjh.v5.i12.666","article-title":"Life cycle and pathogenesis of hepatitis D virus: a review","volume":"5","author":"Abbas","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0395","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1128\/JVI.02083-09","article-title":"Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II","volume":"84","author":"Hong","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0400","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0405","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2019.03.009_b0410","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/jvi.67.12.7659-7662.1993","article-title":"Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen","volume":"67","author":"Hwang","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0415","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/jvi.67.1.366-372.1993","article-title":"Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion","volume":"67","author":"Sureau","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0420","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1073\/pnas.0704000104","article-title":"Involvement of host cellular multivesicular body functions in hepatitis B virus budding","volume":"104","author":"Watanabe","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0425","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/jvi.58.3.945-950.1986","article-title":"Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope","volume":"58","author":"Bonino","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","article-title":"HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes","volume":"136","author":"Alfaiate","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jare.2019.03.009_b0435","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"L\u00fctgehetmann","year":"2012","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0440","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/jvi.65.3.1099-1104.1991","article-title":"Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line","volume":"65","author":"Wu","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0445","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1128\/JVI.01609-10","article-title":"Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses","volume":"85","author":"Pollicino","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0450","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2009.10.036","article-title":"Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D","volume":"52","author":"Schaper","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0455","unstructured":"Raffa G, Niro GA, Raimondo G, Pollicino T. Hepatitis delta virus exerts an epigenetic control over hepatitis B virus transcription\/replication activity. Hepatology, vol. 54, p. 1083A\u20131083A."},{"key":"10.1016\/j.jare.2019.03.009_b0460","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1099\/vir.0.011239-0","article-title":"Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha\/beta interferon-inducible MxA gene","volume":"90","author":"Williams","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5501\/wjv.v6.i2.26","article-title":"Structural and nucleic acid binding properties of hepatitis delta virus small antigen","volume":"6","author":"Alves","year":"2017","journal-title":"World J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0470","first-page":"1","article-title":"Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis","author":"Chen","year":"2018","journal-title":"Biochem Cell Biol Biochim Biol Cell"},{"key":"10.1016\/j.jare.2019.03.009_b0475","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1093\/nar\/gkg857","article-title":"Nucleic acid binding properties of the nucleic acid chaperone domain of hepatitis delta antigen","volume":"31","author":"Wang","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jare.2019.03.009_b0480","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02221-17","article-title":"Relative abundance of integrant-derived viral RNAs in infected tissues harvested from chronic hepatitis B virus carriers","volume":"92","author":"Freitas","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0485","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/jgh.14075","article-title":"Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy","volume":"33","author":"Hu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jare.2019.03.009_b0495","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/JVI.00430-14","article-title":"Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles","volume":"88","author":"Freitas","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2019.03.009_b0500","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jare.2019.03.009_b0505","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0510","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jhep.2015.07.014","article-title":"Early inhibition of hepatocyte innate responses by hepatitis B virus","volume":"63","author":"Luangsay","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0515","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"issue":"1791\u20131804","key":"10.1016\/j.jare.2019.03.009_b0520","article-title":"HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon","volume":"154","author":"Mutz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.03.011","article-title":"Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection","author":"Giersch","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0530","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2018.02.021","article-title":"Hepatitis D virus replication is sensed by MDA5 and induces IFN-\u03b2\/\u03bb responses in hepatocytes","volume":"69","author":"Zhang","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0535","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2019.03.009_b0540","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2004.06.025","article-title":"Interferon-alpha stimulation of liver cells enhances hepatitis delta virus RNA editing in early infection","volume":"41","author":"Hartwig","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0545","article-title":"Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo","author":"Giersch","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0550","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22654","article-title":"Hepatitis delta virus inhibits alpha interferon signaling","volume":"49","author":"Pugnale","year":"2009","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0555","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0560","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","article-title":"Natural history and treatment of chronic delta hepatitis","volume":"17","author":"Yurdayd\u0131n","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0565","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jare.2019.03.009_b0570","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/155.5.931","article-title":"Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B","volume":"155","author":"Fattovich","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0575","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0580","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0585","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/djs168","article-title":"A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma","volume":"104","author":"Ji","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jare.2019.03.009_b0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"B\u00e9guelin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092062","article-title":"High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta","volume":"9","author":"Romeo","year":"2014","journal-title":"PLoS One"},{"issue":"67","key":"10.1016\/j.jare.2019.03.009_b0600","first-page":"370","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"2017","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0605","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/infdis\/jiy157","article-title":"Hepatitis D viremia among injection drug users in San Francisco","volume":"217","author":"Mahale","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jare.2019.03.009_b0615","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0620","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"First international external quality assessment for hepatitis delta virus RNA quantification in plasma","volume":"64","author":"Le Gal","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0625","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/JCM.02027-16","article-title":"Performance characteristics of a new consensus commercial kit for Hepatitis D virus RNA viral load quantification","volume":"55","author":"Le Gal","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jare.2019.03.009_b0630","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2005.00601.x","article-title":"Treatment of hepatitis D","volume":"12","author":"Niro","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0635","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0640","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jare.2019.03.009_b0645","first-page":"CD006002","article-title":"Jafri W. Interferon alpha for chronic hepatitis D","author":"Abbas","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jare.2019.03.009_b0650","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.3748\/wjg.v21.i32.9461","article-title":"Management of hepatitis delta: need for novel therapeutic options","volume":"21","author":"Abbas","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jare.2019.03.009_b0655","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13081","article-title":"New treatment option for delta virus: is a cure in sight?","author":"Yurdaydin","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0660","first-page":"734","article-title":"Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia","volume":"11","author":"Brichler","year":"2013","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jare.2019.03.009_b0665","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jare.2019.03.009_b0670","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/0168-8278(90)90185-T","article-title":"Therapy of chronic delta hepatitis with interferon alfa-2b","volume":"11","author":"Di Bisceglie","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0675","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0168-8278(89)90143-8","article-title":"Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses","volume":"9","author":"Porres","year":"1989","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0680","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0685","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0690","first-page":"805","article-title":"Treatment of chronic hepatitis delta with pegylated interferon-alpha2b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jare.2019.03.009_b0695","first-page":"377","article-title":"Weight-based dosing regimen of peg-interferon \u03b1-2b for chronic hepatitis delta: a multicenter Romanian trial","volume":"20","author":"Gheorghe","year":"2011","journal-title":"J Gastrointest Liver Dis JGLD"},{"key":"10.1016\/j.jare.2019.03.009_b0700","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jare.2019.03.009_b0705","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00162-9","article-title":"Famciclovir treatment of chronic delta hepatitis","volume":"37","author":"Yurdaydin","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0710","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"Gunsar","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jare.2019.03.009_b0715","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jare.2019.03.009_b0720","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0725","first-page":"82","article-title":"Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir","volume":"46","author":"Borzacov","year":"2016","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0730","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1097\/QAD.0000000000000417","article-title":"Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients","volume":"28","author":"Soriano","year":"2014","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.jare.2019.03.009_b0735","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF02253420","article-title":"Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides","volume":"4","author":"Chia","year":"1997","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jare.2019.03.009_b0740","first-page":"496A","article-title":"A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV Study (abstr.)","volume":"66","author":"Hamid","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.009_b0745","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0750","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0755","article-title":"Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with peg-interferon alpha 2a in patients with chronic HBV\/Hdv co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jare.2019.03.009_b0760","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0765","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jare.2019.03.009_b0770","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(17)30310-0","article-title":"A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0775","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis\u2013end of study results from the LOWR HDV-3 study","volume":"66","author":"Koh","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0780","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(18)30397-0","article-title":"Subanalysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads","volume":"68","author":"Yurdaydin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0785","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0790","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/S0168-8278(18)31266-2","article-title":"Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV co-infection: 18 month follow-up results from the REP 301-LTF study","volume":"68","author":"Bazinet","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0795","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0800","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(18)30398-2","article-title":"Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combinationwith Tenofovir in chronic HBV\/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial","volume":"68","author":"Allweiss","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jare.2019.03.009_b0805","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2019.02.009","article-title":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells","volume":"164","author":"Blanchet","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jare.2019.03.009_b0810","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","author":"Vaillant","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jare.2019.03.009_b0815","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1086\/510433","article-title":"Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign","volume":"44","author":"Mele","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jare.2019.03.009_b0820","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0032-1323631","article-title":"Perspectives for a vaccine against hepatitis delta virus","volume":"32","author":"Roggendorf","year":"2012","journal-title":"Semin Liver Dis"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012321930075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012321930075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:46:39Z","timestamp":1761857199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012321930075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":164,"alternative-id":["S209012321930075X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2019.03.009","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on hepatitis D: From virology to new therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}